On July 17, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the broad claims of Compugen’s Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained (Press release, Compugen, JUL 17, 2023, View Source [SID1234633273]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1. In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen. The opponents can appeal this decision.
"We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery." said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
Dr. Cohen-Dayag continued, "PVRIG is a novel immune checkpoint target, discovered by Compugen and along with TIGIT and PD-1 is part of the DNAM-1 axis. Our data suggest that in certain patients and in certain tumor types there is a need to block all three pathways in the DNAM-1 axis and we are currently leading the way in evaluating the triple blockade of PVRIG in combination with TIGIT and PD-1 in two proof of concept studies in tumors typically not responsive to immunotherapy, microsatellite stable colorectal cancer and platinum resistant ovarian cancer."
Compugen was represented by Markus Rieck, LL.M., Partner, Patent Attorney, Fuchs Patentanwälte Partnerschaft mbB and Thomas Wolter, Partner, Patent Attorney, Mewburn Ellis LLP.